Rybelsus (Semaglutide) Patent Expiration, LOE Window & CMS Spending

Rybelsus (Semaglutide) by Novo Nordisk: FDA Orange Book core substance LOE 2034-05-02 (last listed 2039-02-01), 0 AB generics, $2.20B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovo Nordisk
FDA Application & PathwayN213051 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-05-02
Last Listed Patent or Exclusivity Date2039-02-01
Orange Book Patents (*PED Extensions)17 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.20B
2024 Medicare Part D Spend$1.89B
2024 Medicaid Spend$311.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.